Salvage Treatment With Venetoclax (Ven) and Hypomethylating Agents (HMA) for Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia (AML) Patients: Clinical Characteristics and Outcomes

被引：0
|
作者：
Ghorab, Ahmad [1 ]
Litzow, Mark [2 ]
Gangat, Naseema [2 ]
Al-Kali, Aref [2 ]
Shah, Mithun [2 ]
Murthy, Hemant [1 ]
Alkhateeb, Hasan [2 ]
Begna, Kebede [2 ]
Patnaik, Mrinal [2 ]
Foran, James [1 ]
Badar, Talha [1 ]
机构：
[1] Mayo Clin, Jacksonville, FL USA
[2] Mayo Clin, Rochester, MN USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
Relapsed/Refractory AML; FLT3; mutation; Hypomethylating Agents; Venetoclax; Clinical Outcomes;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AML-497
引用
收藏
页码：S306 / S306
页数：1
相关论文
共 50 条
  • [1] Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
    Daver, Naval
    Perl, Alexander E.
    Maly, Joseph
    Levis, Mark
    Ritchie, Ellen
    Litzow, Mark
    McCloskey, James
    Smith, Catherine C.
    Schiller, Gary
    Bradley, Terrence
    Tiu, Ramon, V
    Naqvi, Kiran
    Dail, Monique
    Brackman, Deanna
    Siddani, Satya
    Wang, Jing
    Chyla, Brenda
    Lee, Paul
    Altman, Jessica K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (35) : 4048 - +
  • [2] Venetoclax Plus Hypomethylating Agent (HMA) Based Induction for Treatment-Naive Older/Unfit Patients with FLT3-Mutated Acute Myeloid Leukemia (AML)
    Ghorab, Ahmad
    Litzow, Mark R.
    Gangat, Naseema
    Al-Kali, Aref
    Shah, Mithun, V
    Murthy, Hemant S.
    Tefferi, Ayalew
    Alkhateeb, Hassan B.
    Begna, Kebede
    Patnaik, Mrinal M.
    Foran, James M.
    Badar, Talha
    BLOOD, 2022, 140 : 9019 - 9020
  • [3] Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia
    McMahon, Christine M.
    Perl, Alexander E.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (09) : 841 - 849
  • [4] Real World Treatment Patterns and Outcomes of Venetoclax (Ven) and Hypomethylating Agents (HMA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) in the United States
    Vachhani, Pankit
    Abbas, Jonathan A.
    Flahavan, Evelyn M.
    Ma, Esprit
    Xu, Tao
    Jin, Huan
    Montez, Melissa
    Huang, Weize
    Gershon, Anda
    Ku, Grace
    Flores, Brannon
    Onishi, Maika
    Bui, Cat N.
    Donnellan, William
    BLOOD, 2021, 138
  • [5] Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia
    Kugler, Eitan
    Cohen, Inbar
    Amitai, Irina
    Ram, Ron
    Frisch, Avraham
    Nachmias, Boaz
    Canaani, Jonathan
    Moshe, Yakir
    Krayem, Baher
    Aumann, Shlomzion
    Henig, Israel
    Vainstein, Vladimir
    Shargian, Liat
    Ganzel, Chezi
    Yeshurun, Moshe
    Levi, Itay
    Raanani, Pia
    Akria, Luiza
    Ofran, Yishai
    Shimony, Shai
    Wolach, Ofir
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (03) : 932 - 941
  • [6] Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)
    Ball, Brian J.
    Arslan, Shukaib
    Koller, Paul
    Ngo, Dat
    Afkhami, Michelle
    Salhotra, Amandeep
    Al-Malki, Monzr
    Aribi, Ahmed
    Ali, Haris
    Sandhu, Karamjeet
    Otoukesh, Salman
    Amanam, Idoroenyi
    Pourhassan, Hoda
    Artz, Andrew
    Curtin, Peter
    Stein, Anthony
    Nakamura, Ryotaro
    Marcucci, Guido
    Smith, Eileen
    Pullarkat, Vinod
    Aldoss, Ibrahim
    LEUKEMIA & LYMPHOMA, 2022, 63 (13) : 3232 - 3236
  • [7] Correlative Biomarkers of Response to Venetoclax (VEN) in Combination with Chemotherapy or Hypomethylating Agents (Hma) in Elderly Untreated Patients with Acute Myeloid Leukemia (AML)
    Chyla, B.
    Popovic, R.
    Potluri, J.
    Hayslip, J.
    Huang, X.
    Mabry, M.
    Bhathena, A.
    ANNALS OF HEMATOLOGY, 2017, 96 : S84 - S85
  • [8] Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML
    Short, Nicholas J.
    Daver, Naval
    Dinardo, Courtney D.
    Kadia, Tapan
    Nasr, Lewis F.
    Macaron, Walid
    Yilmaz, Musa
    Borthakur, Gautam
    Montalban-Bravo, Guillermo
    Garcia-Manero, Guillermo
    Issa, Ghayas C.
    Chien, Kelly S.
    Jabbour, Elias
    Nasnas, Cedric
    Huang, Xuelin
    Qiao, Wei
    Matthews, Jairo
    Stojanik, Christopher J.
    Patel, Keyur P.
    Abramova, Regina
    Thankachan, Jennifer
    Konopleva, Marina
    Kantarjian, Hagop
    Ravandi, Farhad
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (13) : 1499 - 1508
  • [9] Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia
    McMahon, Christine M.
    Canaani, Jonathan
    Rea, Bryan
    Sargent, Rachel L.
    Qualtieri, Julianne N.
    Watt, Christopher D.
    Morrissette, Jennifer J. D.
    Carroll, Martin
    Perl, Alexander E.
    BLOOD ADVANCES, 2019, 3 (10) : 1581 - 1585
  • [10] Heterogeneous Definitions of Secondary Acute Myeloid Leukemia (AML) Yield Distinct Outcomes in Response to First-Line Treatment with Hypomethylating Agents (HMA) and Venetoclax (Ven)
    Tan, Irena
    Schwede, Matthew
    Phan, Paul
    Yin, Raymond
    Zhang, Tian Y.
    Mannis, Gabriel N.
    BLOOD, 2021, 138
12345